| Name | Title | Contact Details |
|---|
Divergence is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.